194 related articles for article (PubMed ID: 27913513)
1. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
Hoster E; Pott C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
[TBL] [Abstract][Full Text] [Related]
2. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
Hoster E; Delfau-Larue MH; Macintyre E; Jiang L; Stilgenbauer S; Vehling-Kaiser U; Salles G; Thieblemont C; Tilly H; Wirths S; Feugier P; Hübel K; Schmidt C; Ribrag V; Kluin-Nelemans JC; Dreyling M; Pott C;
J Clin Oncol; 2024 Feb; 42(5):538-549. PubMed ID: 37992261
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
Ladetto M; Tavarozzi R; Pott C
Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
Kumar A; Bantilan KS; Jacob AP; Park A; Schoninger SF; Sauter C; Ulaner GA; Casulo C; Faham M; Kong KA; Grewal RK; Gerecitano J; Hamilton A; Hamlin P; Matasar M; Moskowitz CH; Noy A; Palomba ML; Portlock CS; Younes A; Willis T; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):230-237.e12. PubMed ID: 33558202
[TBL] [Abstract][Full Text] [Related]
6. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
[TBL] [Abstract][Full Text] [Related]
9. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
10. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
12. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
13. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Liu H; Johnson JL; Koval G; Malnassy G; Sher D; Damon LE; Hsi ED; Bucci DM; Linker CA; Cheson BD; Stock W
Haematologica; 2012 Apr; 97(4):579-85. PubMed ID: 22102709
[TBL] [Abstract][Full Text] [Related]
15. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
[TBL] [Abstract][Full Text] [Related]
17. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
[TBL] [Abstract][Full Text] [Related]
18. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.
Spurgeon SE; Till BG; Martin P; Goy AH; Dreyling MP; Gopal AK; LeBlanc M; Leonard JP; Friedberg JW; Baizer L; Little RF; Kahl BS; Smith MR
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 28040733
[TBL] [Abstract][Full Text] [Related]
20. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
